ADA	anti-drug antibodies
ADC	antibody drug conjugate
ADCC	antibody-dependent cell-mediated
ADEPT	antibody-directed enzyme prodrug therapy
CCR	complex chromosomal rearrangement
CD	cluster of differentiation, which identifies cell surface molecules
CRS	cytokine release syndrome
CTLA-4	cytotoxic T-lymphocyte antigen 4
EGFR	epidermal growth factor receptor
Fab	fragment antigen binding
Fc	fragment constant
FIH	First-in-human
IC	immune complex
IgG	immunoglobulin G
IHC	Immunohistochemistry
mAb	monoclonal antibody
MABEL	minimal anticipated biological effect level
MRSD	maximum recommended starting dose
NOAEL	no observable adverse effect level
PD-1	programmed cell death-1
PK/PD	pharmacokinetic/pharmacodynamic
scFv	single chain variable fragments
TCR	tissue cross-reactivity
TNF	tumor necrosis factor
USFDA	United States Food and Drug Administration
VEGF	vascular endothelial growth factor